medroxyprogesterone acetate has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huras, H; Jach, R; Kempisty-Zdebik, E; Ludwin, A; Ludwin, I; Radon-Pokracka, M; Stangel-Wojcikiewicz, K; Wadowska-Jaszczynska, K; Zdebik, A | 1 |
| Balasch, J; Castelo-Branco, C; Durán, M; Fortuny, A; Pons, F; Rovira, M; Sierra, J; Vanrell, J; Vives, A | 1 |
2 other study(ies) available for medroxyprogesterone acetate and Hematologic Malignancies
| Article | Year |
|---|---|
Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.
Topics: Adolescent; Adult; Chemoradiotherapy; Contraceptive Agents, Female; Drug Combinations; Dydrogesterone; Estradiol; Estriol; Female; Follicle Stimulating Hormone, Human; Hematologic Neoplasms; Hormone Replacement Therapy; Humans; Infertility, Female; Luteinizing Hormone; Medroxyprogesterone Acetate; Megestrol; Middle Aged; Ovarian Follicle; Primary Ovarian Insufficiency; Progesterone; Progesterone Congeners; Young Adult | 2012 |
The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation.
Topics: Administration, Cutaneous; Adult; Bone Density; Bone Marrow Transplantation; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hematologic Neoplasms; Humans; Medroxyprogesterone Acetate; Osteoporosis; Primary Ovarian Insufficiency; Progesterone Congeners; Time Factors | 1996 |